Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
The FDA approved the drug in 2022. Administered as chronic IV treatment.On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million.
上週五，意大利製藥公司Recordati S.p.A同意以總額82500萬美元作爲預付款，並向賽諾菲安萬特(SNY)收購全球Enjaymo（sutimlimab）的權利，還包括最高25000萬美元的商業里程碑支付。
Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis).
Enjaymo是一種人源化單克隆抗體，是唯一獲批用於冷凝集素病（CAD）的靶向產品，這是一種罕見的自身免疫性疾病，其特徵是紅細胞（溶血）的過早破壞。
Also Read: FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease.
還閱讀：FDA批准再生成/賽諾菲的億美元抗擊吸菸者肺病的Dupixent。
The FDA approved the drug in 2022. Administered as chronic IV treatment.
FDA於2022年批准該藥。作爲慢性靜脈注射治療。
Enjaymo generated approximately 100 million euros ($109.70 million) in revenue over the last 12 months as of August 2024 and is expected to generate revenue of over 150 million euros in fiscal 2025, with peak sales potential of 250 million-300 million euros, more than double current levels.
Enjaymo在截至2024年8月的過去12個月中產生了約10000萬歐元（10970萬美元）的營業收入，並預計在2025財年將產生超過15000萬歐元的收入，銷售潛力達到25000萬-30000萬歐元，是目前水平的兩倍多。
Subject to the closing date, Recordati expects minimal revenue contribution in 2024. The transaction is expected to close by the end of 2024.
取決於交割日期，Recordati預計2024年對收入的貢獻微乎其微。交易預計將在2024年年底前完成。
The transaction is expected to be immediately accretive at the EBITDA level, with the margin above the current Rare Diseases average as of 2025.
該交易預計在2025年EIBTDA層面立即實現增加，利潤率高於截至2025年的當前罕見疾病平均水平。
The deal will be funded by existing cash and new committed bank debt facilities. Net debt is expected to be approximately 2.4 – 2.5x EBITDA (Pro-forma) at the end of 2024, de-leveraging to less than 2.0x EBITDA at the end of 2025, assuming no additional business development transactions.
該交易將由現有現金和新的承諾的銀行債務設施資助。截至2024年底，淨債務預計約爲EBITDA（稅前利潤、稅前利息、折舊和攤銷前利潤）的2.4-2.5倍，預計在2025年底降至低於EBITDA的2.0倍，假設沒有額外的業務發展交易。
In September, Sanofi agreed to make a $27 million strategic investment in Ventyx Biosciences Inc. The company also agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights.
賽諾菲安萬特同意對Ventyx Biosciences Inc進行2700萬美元的戰略投資。該公司還同意授予賽諾菲對於特定VTX3232項目權益的獨家首談權。
Price Action: SNY stock is up 0.31% at $55.71 at last check Friday.
股價走勢：SNY股價在上週五最後一次查詢時上漲0.31%，達55.71美元。
Photo via Shutterstock
圖片來自shutterstock。
- Rivian's Production Forecast Hits Bump, Supply Shortage Sends Shares Tumbling.
- Rivian的生產預測受挫，供應短缺導致股價下跌。